Milestone Pharmaceuticals Announces First European Patient Enrolled In Phase 3 Trial Of Etripamil For Atrial Fibrillation With Rapid Heart Rate
Share
Why It Matters
Milestone Pharmaceuticals started testing a heart medicine in Europe. Watch this trial to see if the drug works and could reach more patients.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.